Molecular and Clinical Aspects of Angelman Syndrome

被引:89
作者
Dagli, A. [1 ]
Buiting, K. [2 ]
Williams, C. A. [1 ]
机构
[1] Univ Florida, Dept Pediat, Div Genet & Metab, Raymond C Philips Unit, Gainesville, FL 32610 USA
[2] Univ Klinikum Essen, Inst Humangenet, Essen, Germany
关键词
Angelman syndrome; Imprinting; Microdeletion; 15q11.2-q13; UBE3A; Ubiquitin;
D O I
10.1159/000328837
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The Angelman syndrome is caused by disruption of the UBE3A gene and is clinically delineated by the combination of severe mental disability, seizures, absent speech, hypermotoric and ataxic movements, and certain remarkable behaviors. Those with the syndrome have a predisposition toward apparent happiness and paroxysms of laughter, and this finding helps distinguish Angelman syndrome from other conditions involving severe developmental handicap. Accurate diagnosis rests on a combination of clinical criteria and molecular and/or cytogenetic testing. Analysis of parent-specific DNA methylation imprints in the critical 15q11.2q13 genomic region identifies 75-80% of all individuals with the syndrome, including those with cytogenetic deletions, imprinting center defects and paternal uniparental disomy. In the remaining group, UBE3A sequence analysis identifies an additional percentage of patients, but 5-10% will remain who appear to have the major clinical phenotypic features but do not have any identifiable genetic abnormalities. Genetic counseling for recurrence risk is complicated because multiple genetic mechanisms can disrupt the UBE3A gene, and there is also a unique inheritance pattern associated with UBE3A imprinting. Angelman syndrome is a prototypical developmental syndrome due to its remarkable behavioral phenotype and because UBE3A is so crucial to normal synaptic function and neural plasticity. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:100 / 112
页数:13
相关论文
共 50 条
  • [31] The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders
    Barbara J Bailus
    David J Segal
    BMC Neuroscience, 15
  • [32] Angelman syndrome in adulthood
    Lorenzo-Ruiz, Maria
    Novo-Ponte, Sabela
    Iglesias-Escalera, Gema
    Cazorla-Calleja, Rosario
    Lara-Herguedas, Julian
    Lopez-Pajaro, Luis F.
    Ruiz-Antoran, Belen
    REVISTA DE NEUROLOGIA, 2023, 76 (07) : 217 - 226
  • [33] Epilepsy in Angelman syndrome
    Pelc, Karine
    Boyd, Stewart G.
    Cheron, Guy
    Dan, Bernard
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2008, 17 (03): : 211 - 217
  • [34] Angelman syndrome revisited
    Paprocka, Justyna
    Jamroz, Ewa
    Szwed-Bialoiyt, Barbara
    Jezela-Stanek, Aleksandra
    Kopyta, Ilona
    Marszal, Elibieta
    NEUROLOGIST, 2007, 13 (05) : 305 - 312
  • [35] A Streamlined Approach to Prader-Willi and Angelman Syndrome Molecular Diagnostics
    Strom, Samuel P.
    Hossain, Waheeda A.
    Grigorian, Melina
    Li, Mickey
    Fierro, Joseph
    Scaringe, William
    Yen, Hai-Yun
    Teguh, Mirandy
    Liu, Joanna
    Gao, Harry
    Butler, Merlin G.
    FRONTIERS IN GENETICS, 2021, 12
  • [36] Anxiety in Angelman Syndrome
    Grebe, Stacey C.
    Limon, Danica L.
    McNeel, Morgan M.
    Guzick, Andrew
    Peters, Sarika U.
    Tan, Wen-Hann
    Sadhwani, Anjali
    Bacino, Carlos A.
    Bird, Lynne M.
    Samaco, Rodney C.
    Berry, Leandra N.
    Goodman, Wayne K.
    Schneider, Sophie C.
    Storch, Eric A.
    AJIDD-AMERICAN JOURNAL ON INTELLECTUAL AND DEVELOPMENTAL DISABILITIES, 2022, 127 (01): : 1 - 10
  • [37] Counselling dilemmas associated with the molecular characterisation of two Angelman syndrome families
    Gilbert, HL
    Buxton, JL
    Chan, CTJ
    McKay, T
    Cottrell, S
    Ramsden, S
    Winter, RM
    Pembrey, ME
    Malcolm, S
    JOURNAL OF MEDICAL GENETICS, 1997, 34 (08) : 651 - 655
  • [38] Genotype-Phenotype Correlations in Angelman Syndrome
    Yang, Lili
    Shu, Xiaoli
    Mao, Shujiong
    Wang, Yi
    Du, Xiaonan
    Zou, Chaochun
    GENES, 2021, 12 (07)
  • [39] Analysis of the characteristics of epilepsy in 37 patients with the molecular diagnosis of Angelman syndrome
    Galván-Manso, M
    Campistol, J
    Conill, J
    Sanmartí, FX
    EPILEPTIC DISORDERS, 2005, 7 (01) : 19 - 25
  • [40] The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders
    Bailus, Barbara J.
    Segal, David J.
    BMC NEUROSCIENCE, 2014, 15